Artificial Intelligence (AI) For De Novo Drug Design Global Market Report 2026

Description

Artificial intelligence (AI) for de novo drug design involves using machine learning and computational algorithms to generate novel molecular structures with targeted biological properties. It employs pattern recognition, predictive modeling, and optimization techniques to efficiently explore vast chemical spaces. AI-driven approaches accelerate the discovery of potential drug candidates while reducing reliance on conventional trial-and-error methods.

The primary components of artificial intelligence (AI) for de novo drug design include software and services. Software platforms leverage AI algorithms to accelerate drug discovery, including target identification and lead compound optimization. Therapeutic areas include oncology, neurological disorders, infectious diseases, cardiovascular diseases, rare diseases, metabolic disorders, and other indications. Deployment occurs via on-premises and cloud-based solutions, serving applications such as target identification, lead compound generation, molecular property prediction, absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction, and others, with end users including pharmaceutical companies, biotechnology firms, academic and research institutes, contract research organizations, and other sectors.

Tariffs on imported computational hardware, specialized AI processors, and molecular modeling software components are impacting the AI for de novo drug design market by increasing costs for software providers and research organizations. Segments such as cloud-based software and deep learning platforms, especially in North America, Europe, and Asia-Pacific, are most affected. While tariffs elevate operational expenses, they also incentivize domestic hardware production, regional software development, and innovation in cost-efficient AI drug design platforms, enhancing local capabilities and supply chain resilience.

The artificial intelligence (AI) for de novo drug design market research report is one of a series of new reports from The Business Research Company that provides artificial intelligence (AI) for de novo drug design market statistics, including artificial intelligence (AI) for de novo drug design industry global market size, regional shares, competitors with a artificial intelligence (AI) for de novo drug design market share, detailed artificial intelligence (AI) for de novo drug design market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) for de novo drug design industry. This artificial intelligence (AI) for de novo drug design market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The artificial intelligence (AI) for de novo drug design market size has grown exponentially in recent years. It will grow from $1.9 billion in 2025 to $2.53 billion in 2026 at a compound annual growth rate (CAGR) of 33.4%. The growth in the historic period can be attributed to high r&d costs in traditional drug discovery, growing demand for faster drug development, adoption of computational chemistry tools, increasing pharmaceutical investments, expansion of academic and research collaborations.

The artificial intelligence (AI) for de novo drug design market size is expected to see exponential growth in the next few years. It will grow to $8.07 billion in 2030 at a compound annual growth rate (CAGR) of 33.7%. The growth in the forecast period can be attributed to growing adoption of ai-driven lead compound generation, increasing use of admet prediction models, rising integration of cloud and on-premises deployment, expansion of model development and data annotation services, growing collaboration between pharmaceutical and biotech companies. Major trends in the forecast period include increasing adoption of cloud-based ai platforms, rising demand for deep learning-based drug design software, growing integration of workflow automation in drug discovery, expansion of molecular property prediction tools, rising focus on targeted therapeutic area applications.

The rising prevalence of complex diseases is projected to accelerate the growth of the artificial intelligence (AI) for the de novo drug design market moving forward. Complex diseases are health disorders resulting from a combination of genetic, environmental, and lifestyle influences, often affecting multiple body systems and requiring advanced or prolonged medical care. The prevalence of complex diseases is increasing due to unhealthy lifestyle behaviors, which heighten the likelihood of chronic conditions such as diabetes, cardiovascular disorders, and certain types of cancer. Artificial intelligence (AI) for de novo drug design advances the discovery of innovative therapies by processing complex biological datasets and forecasting effective drug candidates, thereby addressing the difficulties associated with multifactorial and long-term complex diseases. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization, more than 35 million new cancer cases are anticipated by 2050, reflecting a 77% increase compared to the estimated 20 million cases recorded in 2022. Therefore, the rising prevalence of complex diseases is driving the growth of the artificial intelligence (AI) for de novo drug design market.

Key companies operating in the artificial intelligence (AI) for de novo drug design market are focusing on developing innovative solutions, such as artificial intelligence (AI)-native drug discovery platforms, to accelerate the design and optimization of novel small molecules. Artificial intelligence (AI)-native drug discovery platforms are integrated systems that use AI models to generate, predict, and select novel molecules from scratch, helping accelerate drug discovery by identifying promising compounds faster and more efficiently than traditional trial-and-error methods. For example, in November 2025, Terray Therapeutics, a US-based biotechnology company, launched EMMI (Experimentation Meets Machine Intelligence), an AI-native drug discovery platform specifically engineered for de novo small molecule design. It integrates Terray Therapeutics' proprietary ultra-miniaturized experimental hardware with a highly automated laboratory environment and the Chemistry-Oriented AI Transformer Interface, third generation (COATI3) chemistry foundation model, to generate millions of novel molecules, predict their potency, identify the most promising candidates, and iteratively refine them. The platform's generative AI leverages reinforcement learning to propose synthetically accessible molecules, while predictive AI models rapidly assess properties such as potency, selectivity, solubility, metabolism, and clearance, and the selection AI determines which molecules to synthesize to reduce time and cost by up to threefold compared to industry standards. EMMI has applications across internal immunology programs as well as strategic partnerships targeting previously unexplored chemical space, making it a transformative solution for de novo drug design.

In July 2023, BioNTech SE, a Germany-based biopharmaceutical technology company, finalized the acquisition of InstaDeep Ltd. for $549 million (€500 million). With this acquisition, BioNTech intended to reinforce and broaden its strategic capabilities in artificial intelligence-enabled drug discovery and development by incorporating advanced AI and machine learning technologies to speed up the creation of next-generation immunotherapies and vaccines. InstaDeep Ltd. is a UK-based technology company that focuses on delivering advanced artificial intelligence and machine learning solutions that facilitate de novo drug design.

Major companies operating in the artificial intelligence (AI) for de novo drug design market are Schrodinger Inc., XtalPi Holdings Ltd., Owkin Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Deep Genomics Inc., Iktos SA, Atomwise Inc., Terray Therapeutics Inc., Evogene Ltd., Genesis Therapeutics Inc., Insitro Inc., Verge Genomics Inc., DeepCure Inc., Cloud Pharmaceuticals Inc., Gero LLC, Chai Discovery Inc., Latent Labs Ltd., BioAge Labs Inc., Peptone Ltd., Generate Biomedicines Inc.

North America was the largest region in the artificial intelligence (AI) for de novo drug design market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) for de novo drug design market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the artificial intelligence (AI) for de novo drug design market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The artificial intelligence (AI) for de novo drug design market consists of revenues earned by entities by providing services such as molecular design and generation, target identification and validation, lead optimization, predictive modeling and simulation, data analysis and integration, and virtual screening. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Artificial Intelligence (AI) For De Novo Drug Design Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses artificial intelligence (ai) for de novo drug design market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for artificial intelligence (ai) for de novo drug design ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The artificial intelligence (ai) for de novo drug design market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Component: Software; Services
2) By Therapeutic Area: Oncology; Neurological Disorders; Infectious Diseases; Cardiovascular Diseases; Rare Diseases; Metabolic Disorders; Other Therapeutic Areas
3) By Deployment Mode: On-Premises; Cloud-Based
4) By Application: Target Identification; Lead Compound Generation; Molecular Property Prediction; Absorption, Distribution, Metabolism, Excretion, And Toxicity (ADMET Prediction); Other Applications
5) By End User: Pharmaceutical Companies; Biotechnology Companies; Academic And Research Institutes; Contract Research Organizations; Other End Users
Subsegments:
1) By Software: Cloud Based Software; On Premise Software; Machine Learning Software; Deep Learning Software; Molecular Modeling Software; Data Analytics Software; Workflow Automation Software
2) By Services: Consulting Services; Integration Services; Maintenance And Support Services; Training And Education Services; Managed Services; Data Annotation Services; Model Development Services
Companies Mentioned: Schrodinger Inc.; XtalPi Holdings Ltd.; Owkin Inc.; Insilico Medicine Inc.; Recursion Pharmaceuticals Inc.; Deep Genomics Inc.; Iktos SA; Atomwise Inc.; Terray Therapeutics Inc.; Evogene Ltd.; Genesis Therapeutics Inc.; Insitro Inc.; Verge Genomics Inc.; DeepCure Inc.; Cloud Pharmaceuticals Inc.; Gero LLC; Chai Discovery Inc.; Latent Labs Ltd.; BioAge Labs Inc.; Peptone Ltd.; Generate Biomedicines Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH4MAIAD42_G26Q2

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Artificial Intelligence (AI) For De Novo Drug Design Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Artificial Intelligence (AI) For De Novo Drug Design Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Artificial Intelligence (AI) For De Novo Drug Design Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Artificial Intelligence (AI) For De Novo Drug Design Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Artificial Intelligence & Autonomous Intelligence
- 4.1.2 Biotechnology, Genomics & Precision Medicine
- 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.4 Industry 4.0 & Intelligent Manufacturing
- 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
- 4.2.1 Increasing Adoption of Cloud-Based AI Platforms
- 4.2.2 Rising Demand for Deep Learning-Based Drug Design Software
- 4.2.3 Growing Integration of Workflow Automation in Drug Discovery
- 4.2.4 Expansion of Molecular Property Prediction Tools
- 4.2.5 Rising Focus on Targeted Therapeutic Area Applications

5. Artificial Intelligence (AI) For De Novo Drug Design Market Analysis Of End Use Industries

5.1 Pharmaceutical Companies
5.2 Biotechnology Companies
5.3 Academic And Research Institutes
5.4 Contract Research Organizations
5.5 Healthcare Research Laboratories

6. Artificial Intelligence (AI) For De Novo Drug Design Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Artificial Intelligence (AI) For De Novo Drug Design Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Artificial Intelligence (AI) For De Novo Drug Design PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Artificial Intelligence (AI) For De Novo Drug Design Market Size, Comparisons And Growth Rate Analysis
7.3. Global Artificial Intelligence (AI) For De Novo Drug Design Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Artificial Intelligence (AI) For De Novo Drug Design Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Artificial Intelligence (AI) For De Novo Drug Design Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Artificial Intelligence (AI) For De Novo Drug Design Market Segmentation

9.1. Global Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Software, Services
9.2. Global Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Oncology, Neurological Disorders, Infectious Diseases, Cardiovascular Diseases, Rare Diseases, Metabolic Disorders, Other Therapeutic Areas
9.3. Global Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
On-Premises, Cloud-Based
9.4. Global Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Target Identification, Lead Compound Generation, Molecular Property Prediction, Absorption, Distribution, Metabolism, Excretion, And Toxicity (ADMET Prediction), Other Applications
9.5. Global Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations, Other End Users
9.6. Global Artificial Intelligence (AI) For De Novo Drug Design Market, Sub-Segmentation Of Software, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Cloud Based Software, On Premise Software, Machine Learning Software, Deep Learning Software, Molecular Modeling Software, Data Analytics Software, Workflow Automation Software
9.7. Global Artificial Intelligence (AI) For De Novo Drug Design Market, Sub-Segmentation Of Services, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Consulting Services, Integration Services, Maintenance And Support Services, Training And Education Services, Managed Services, Data Annotation Services, Model Development Services

10. Artificial Intelligence (AI) For De Novo Drug Design Market Regional And Country Analysis

10.1. Global Artificial Intelligence (AI) For De Novo Drug Design Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Artificial Intelligence (AI) For De Novo Drug Design Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Artificial Intelligence (AI) For De Novo Drug Design Market

11.1. Asia-Pacific Artificial Intelligence (AI) For De Novo Drug Design Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Artificial Intelligence (AI) For De Novo Drug Design Market

12.1. China Artificial Intelligence (AI) For De Novo Drug Design Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Artificial Intelligence (AI) For De Novo Drug Design Market

13.1. India Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Artificial Intelligence (AI) For De Novo Drug Design Market

14.1. Japan Artificial Intelligence (AI) For De Novo Drug Design Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Artificial Intelligence (AI) For De Novo Drug Design Market

15.1. Australia Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Artificial Intelligence (AI) For De Novo Drug Design Market

16.1. Indonesia Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Artificial Intelligence (AI) For De Novo Drug Design Market

17.1. South Korea Artificial Intelligence (AI) For De Novo Drug Design Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Artificial Intelligence (AI) For De Novo Drug Design Market

18.1. Taiwan Artificial Intelligence (AI) For De Novo Drug Design Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Artificial Intelligence (AI) For De Novo Drug Design Market

19.1. South East Asia Artificial Intelligence (AI) For De Novo Drug Design Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Artificial Intelligence (AI) For De Novo Drug Design Market

20.1. Western Europe Artificial Intelligence (AI) For De Novo Drug Design Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Artificial Intelligence (AI) For De Novo Drug Design Market

21.1. UK Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Artificial Intelligence (AI) For De Novo Drug Design Market

22.1. Germany Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Artificial Intelligence (AI) For De Novo Drug Design Market

23.1. France Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Artificial Intelligence (AI) For De Novo Drug Design Market

24.1. Italy Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Artificial Intelligence (AI) For De Novo Drug Design Market

25.1. Spain Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Artificial Intelligence (AI) For De Novo Drug Design Market

26.1. Eastern Europe Artificial Intelligence (AI) For De Novo Drug Design Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Artificial Intelligence (AI) For De Novo Drug Design Market

27.1. Russia Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Artificial Intelligence (AI) For De Novo Drug Design Market

28.1. North America Artificial Intelligence (AI) For De Novo Drug Design Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Artificial Intelligence (AI) For De Novo Drug Design Market

29.1. USA Artificial Intelligence (AI) For De Novo Drug Design Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Artificial Intelligence (AI) For De Novo Drug Design Market

30.1. Canada Artificial Intelligence (AI) For De Novo Drug Design Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Artificial Intelligence (AI) For De Novo Drug Design Market

31.1. South America Artificial Intelligence (AI) For De Novo Drug Design Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Artificial Intelligence (AI) For De Novo Drug Design Market

32.1. Brazil Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Artificial Intelligence (AI) For De Novo Drug Design Market

33.1. Middle East Artificial Intelligence (AI) For De Novo Drug Design Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Artificial Intelligence (AI) For De Novo Drug Design Market

34.1. Africa Artificial Intelligence (AI) For De Novo Drug Design Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Artificial Intelligence (AI) For De Novo Drug Design Market Regulatory and Investment Landscape

36. Artificial Intelligence (AI) For De Novo Drug Design Market Competitive Landscape And Company Profiles

36.1. Artificial Intelligence (AI) For De Novo Drug Design Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Artificial Intelligence (AI) For De Novo Drug Design Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Artificial Intelligence (AI) For De Novo Drug Design Market Company Profiles
- 36.3.1. Schrodinger Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. XtalPi Holdings Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Owkin Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Insilico Medicine Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Recursion Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Artificial Intelligence (AI) For De Novo Drug Design Market Other Major And Innovative Companies

Deep Genomics Inc., Iktos SA, Atomwise Inc., Terray Therapeutics Inc., Evogene Ltd., Genesis Therapeutics Inc., Insitro Inc., Verge Genomics Inc., DeepCure Inc., Cloud Pharmaceuticals Inc., Gero LLC, Chai Discovery Inc., Latent Labs Ltd., BioAge Labs Inc., Peptone Ltd.

38. Global Artificial Intelligence (AI) For De Novo Drug Design Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Artificial Intelligence (AI) For De Novo Drug Design Market

41. Artificial Intelligence (AI) For De Novo Drug Design Market High Potential Countries, Segments and Strategies

41.1 Artificial Intelligence (AI) For De Novo Drug Design Market In 2030 - Countries Offering Most New Opportunities
41.2 Artificial Intelligence (AI) For De Novo Drug Design Market In 2030 - Segments Offering Most New Opportunities
41.3 Artificial Intelligence (AI) For De Novo Drug Design Market In 2030 - Growth Strategies
- 41.3.1 Market Trend Based Strategies
- 41.3.2 Competitor Strategies

42. Appendix

42.1. Abbreviations
42.2. Currencies
42.3. Historic And Forecast Inflation Rates
42.4. Research Inquiries
42.5. The Business Research Company
42.6. Copyright And Disclaimer